AI-Powered Liver Fibrosis Detection & Risk Stratification
Liver fibrosis can develop silently. RegenExoBio participates in a collaborative project in the USA exploring AI and clinical parameters to support detection and assessment of liver fibrosis risk.
Making AI a Reality for Liver Health
This project explores how artificial intelligence, clinical data and medical knowledge may help clinicians assess liver fibrosis more effectively.
Our Focus
Why Early Detection Matters
In early stages, liver fibrosis may not cause symptoms. An approach that identifies people who may be at increased risk could help support timely clinical evaluation.
Our Development Pathway
A US-Based Collaborative Initiative
The initiative brings together complementary capabilities to explore AI-enabled liver health assessment. We believe in the development of innovative technologies that bridge the gap between scientific knowledge and its application in health care at RegenExoBio.
Working Towards Regulatory Readiness
Clinical evaluation, quality processes and regulatory compliance are important steps on the path toward clinical use. A future CDSCO pathway in India will be considered subject to successful validation and applicable requirements.
Where RegenExoBio Fits In
RegenExoBio works across biotechnology consulting, scientific advisory, healthcare innovation and regenerative medicine, connecting scientific development with strategic and regulatory planning.
AI, clinical science, biotechnology and healthcare
Bringing data to insights. Insights to informed decisions.
Liver Health Assessment: Making it Smarter.
Investigating a smarter approach to liver fibrosis risk stratification using AI, clinical information and expert validation.